Details of the Drug Combinations

General Information of This Drug (ID: DMY38SB)

• Drug Name: CATECHIN (DMY38SB)
• Synonyms: Cianidanol; (+)-catechin; 154-23-4; Catechuic acid; Cyanidanol; Catechinic acid; D-Catechin; Catergen; Cianidol; (+)-Cyanidanol; (+)-Cyanidan-3-ol; Biocatechin; (+)-Catechin Hydrate; D-(+)-Catechin; Dexcyanidanol; Catechin (flavan); Catechol (flavan); D-Catechol; (2R,3S)-Catechin; (2R,3S)-2-(3,4-Dihydroxyphenyl)chroman-3,5,7-triol; Gambier; 3-Cyanidanol, (+)-; Cianidanolum; Catechu; Transepar; Katha; (2R,3S)-(+)-Catechin; Cutch (dye); (+)-Cianidanol; 3,3',4',5,7-Flavanpentol; KB-53; (+)-Cyanidanol-3; CCRIS 6855

Indication

Discovery agent; ICD 11: N.A.; Status: Investigative [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Docetaxel + CATECHIN	DC1DKCA	Docetaxel	Breast Cancer	[2]
Fludarabine + CATECHIN	DCKC5EJ	Fludarabine	Hematological Malignancies	[3]
Pravastatin + CATECHIN	DCXHG7P	Pravastatin	Dyslipidemias	[4]
Simvastatin + CATECHIN	DCT3SFI	Simvastatin	Dyslipidemias	[4]
Selinexor + CATECHIN	DCKRRV7	Selinexor	Acute Myeloid Leukemia (Relapsed/Refractory)	[5]

References

• [1] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [2] ClinicalTrials.gov (NCT00887536) A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
• [3] ClinicalTrials.gov (NCT03344705) Safety and Efficacy Evaluation of IM19 Cells
• [4] ClinicalTrials.gov (NCT02431013) Cilostazol-Simvastatin Drug Interaction Study
• [5] ClinicalTrials.gov (NCT05951855) Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients